Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion.
German pharmaceutical giant Merck has received notice from British drugmaker Hikma Pharmaceuticals seeking pre-patent expiry approval from the US FDA for the marketing of a generic version of Merck’s Bridion injection in the US.
In a Securities and Exchange Commission (SEC) filing disclosed by Merck, Hikma notified the German company of their intention to seek FDA approval ahead of patent expiry on February 5, 2024 under the Hatch-Waxman Act (also termed the Drug Price Competition and Patent Term Restoration Act of 1984). Under the Hatch-Waxman Act, a company can seek approval to market a generic drug before the expiration of patents for a brand-name product. Merck thus has 45 days from Hikma’s notification to file an infringement suit. Should they choose to do so, approval of Hikma’s product will be delayed for 30 months until either the patent expires, or a judge decides against Merck.
The Hatch-Waxman Act provides a legal framework for streamlining generic pharmaceutical approvals while continuing to incentivise pharmaceutical innovation. The act’s intention is to balance innovation by providing incentives for biopharma to research and develop new pharmaceuticals, while facilitating market approval for generic manufacturers in bringing affordable essential medications to market.
Bridion, the pharmaceutical product in question, is an injection currently approved for reversing the effects of muscle relaxants used during surgeries. The patent is currently protected by a US District Court for the District of New Jersey order until at least January 2026. It was approved in 2015 and remains one of Merck’s top-selling products. In 2023, Bridion brought in just over US$1.8 billion for Merck. Patent expirations for the injectable has already occurred in the EU, Japan, and China.
Future implications of any action taken by Merck and subsequent regulatory and court decisions will set significant precents for any patent disputes in the future. Last year, AbbVie’s blockbuster arthritis treatment Humira lost its patent, allowing biosimilar manufacturers to enter the market at significantly lower price points. With many more brand-name products closing in on their patent expiry dates, decisions made in the coming weeks could shape the future legal and regulatory landscape of pharmaceuticals. Merck has stated they are currently “evaluating its options”.
Sources
1. Merck’s Bridion faces generic threat from drugmaker Hikma [Accessed February 27, 2024] https://www.reuters.com/business/healthcare-pharmaceuticals/mercks-bridion-faces-generic-threat-drugmaker-hikma-2024-02-26/
2. Merck’s Bridion Could Face Generic Pressure from Hikma Ahead of Patent Expiry Date [Accessed Febraury 27, 2024] https://www.biospace.com/article/merck-s-bridion-could-face-generic-pressure-from-hikma-ahead-of-patent-expiry-date/
3. Merck SEC filing [Accessed February 27, 2024] https://d18rn0p25nwr6d.cloudfront.net/CIK-0000064978/4abbf601-f36f-4016-ae6f-a07650f3b571.pdf
4. What is Hatch-Waxman White Sheet [Accessed February 27, 2024] https://phrma.org/-/media/Project/PhRMA/PhRMA-Org/PhRMA-Org/PDF/D-F/Fact-Sheet_What-is-Hatch-Waxman_June-2018.pdf
Related News
-
News Wegovy® – the weight-loss drug sparking a global race to end obesity
Wegovy®, the weight loss drug from Novo Nordisk has been creating headlines since it’s early testing phases, through it’s approval in June 2021 by the US FDA and January 2022 from the European Medicines Agency, and it continues to do so... -
News US FDA approves three different oncology drugs in 1 week
In the last week, the US FDA has granted approval/accelerated approval to three different oncology drugs, each from different drugmakers with different indications. -
News What the Novo Holdings and Catalent deal means for pharma outsourcing
On February 5, 2024, Novo Holdings announced their intention to acquire pharma and biotech CDMO Catalent at US$16.5 billion. Read more about what this means for the pharmaceutical industry as a whole, from drugmakers to their partners in manufacturing.... -
News Key takeaways from Saudi Arabia's National Biotechnology Strategy
In January 2024, Saudi Arabia released its National Biotech Strategy, an ambitious plan to localise biomanufacturing, incentivise R&D and establish the Kingdom as the regional biotech leader by 2030, and an internationally recognised hub by 2040. -
News Novo Holdings buys CDMO Catalent in US$16.5 billion deal
Novo Nordisk’s holding and investment parent company will acquire the publicly owned CDMO at the end of 2024, taking it private and selling three of its drug manufacturing facilities to Novo Nordisk. -
News Special Edition Women in Pharma: International Day of Women and Girls in Science
In this monthly series, we bring insightful content, events, and communities dedicated to sharing best practices for DE&I strategies and showcasing underrepresented voices in the pharmaceutical community. -
News Pharmapack Awards 2024 Start-up Innovation Award Winner – Capa Valve Ltd
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance